Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Jul 21;89(2):232-8.
doi: 10.1038/sj.bjc.6601118.

Survival analysis part I: basic concepts and first analyses

Affiliations
Review

Survival analysis part I: basic concepts and first analyses

T G Clark et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Converting calendar time in the ovarian cancer study to a survival analysis format. Dashed vertical line is the date of the last follow-up, R=relapse, D=death from ovarian cancer, Do=death from other cause, A=attended last clinic visit (alive), L=loss to follow-up, X=death, □=censored.
Figure 2
Figure 2
Relapse-free survival curves for the lung cancer trial. * Median relapse-free survival time for each arm, + censoring times, CAP=cytoxan, doxorubicin and platinum-based chemotherapy.
Figure 3
Figure 3
Survival and cumulative hazard curves with 95% CIs for the ovarian cancer study. Std.Err=standard error. (A) Kaplan–Meier survivor function, (B) cumulative incidence curve, (C) cumulative hazard function, (D) hazard function (smoothed).
Figure 4
Figure 4
Relationships between (parametric) hazard and survival curves: (a) constant hazard (e.g. healthy persons), (b) increasing Weibull (e.g. leukaemia patients), (c) decreasing Weibull (e.g. patients recovering from surgery), (d) increasing and then decreasing log-normal (e.g. tuberculosis patients).
Figure 5
Figure 5
FIGO stage and prognosis in the ovarian study. Chisq=χ2.

Similar articles

Cited by

References

    1. Altman DG (2003) Practical statistics for medical research. London: Chapman & Hall
    1. Altman DG, Bland JM (2003) Statistics notes: interaction revisited: the difference between two estimates. BMJ 326: 219. - PMC - PubMed
    1. Clark TG, Altman DG, De Stavola BL (2002) Quantifying the completeness of follow-up. Lancet 359: 1309–1310 - PubMed
    1. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth J (2001) A prognostic model for ovarian cancer. Br J Cancer 85: 944–952 - PMC - PubMed
    1. Collett D (1994) Modelling Survival Data in Medical Research. London: Chapman & Hall

Publication types